Table 1.
Clinical trial details
| Study | Phase | Intervention |
N
evaluable patients |
% Total | Median follow-up (years)a |
N
survival eventsb |
|---|---|---|---|---|---|---|
| S9321 | 3 | VBMCP vs. Mel+TBI+SCT |
788 | 27.2 | 9.0 | 481 |
| S0204 | 2 | Thal→ Tandem SCT→Thalidomide maintenance | 130 | 4.5 | 9.9 | 53 |
| S0232 | 3 | Dex+/−Len | 176 | 6.1 | 6.7 | 89 |
| E9486 | 3 | VBMCP vs. VBMCP+IFN α vs. VBMCP+Cyclophosphamide | 648 | 22.4 | 12.8 | 492 |
| E5A93 | 3 | VBMCP vs. VBMCP+IFN α or Cyclophosphamide | 222 | 7.7 | 9.9 | 164 |
| E1A00 | 3 | Dex+/−Thal | 205 | 7.1 | 8.0 | 128 |
| E2A02 | 2 | Bortezomib | 40 | 1.4 | 6.0 | 25 |
| E4A03 | 3 | Len+low vs. high dose Dex | 402 | 13.9 | 7.0 | 191 |
| E1A06 | 3 | Mel, Prednisone+Thal vs. Len | 285 | 9.8 | 4.9 | 159 |
VBMCP Vincristine/BCNU/Melphalan/Cyclophosphamide/Prednisone, Mel myeloablative melphalan, TBI total body irradiation, SCT stem cell transplant, Len lenalidomide, Thal thalidomide, Dex dexamethasone, IFN interferon
aIn the absence of censoring
bFollow-up was censored at 6 years for all studies